CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have ...
CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
4d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
2d
Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns
If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk ...
Clearance mechanisms are key to removing aggregates and maintaining metastability.
NEW YORK, NY, UNITED STATES, February 18, 2026 /EINPresswire.com/ -- DataArt, a global software engineering firm that ...
Complex 3D structures of cells called organoids could be used to test treatments for spinal-cord damage that can lead to ...
The Johns Hopkins-created maps provide higher resolution and better coverage of gray matter than previously published maps, ...
Innovations in imaging and genetic engineering are coming together to probe the biophysics of cytoplasm inside living animals.
Precise coordination of cell growth and cell-cycle progression is essential for maintaining tissue integrity and organismal health. When these regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results